A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Trial Profile

A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2016

At a glance

  • Drugs Seribantumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 18 May 2016 Results from this and 2 other trials were presented at the AACR Precision Medicine Series, according to a Merrimack Pharmaceuticals media release.
    • 30 Sep 2014 According to a Merrimack Pharmaceuticals media release, biomarker data was presented at the European Society of Medical Oncology (ESMO) 2014 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top